|
Aug 07, 2019
|
Catalyst Pharmaceuticals Announces Second Quarter 2019 Financial Results and Provides Corporate Update
Firdapse ® Launch Momentum Continues with Second Quarter Net Revenues of $28.8 Million 409 Adult LEMS Patients Active on Firdapse as of June 30, 2019 Company to Host Quarterly Conference Call at 8:30 am ET Tomorrow CORAL GABLES, Fla. , Aug. 07, 2019 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals,
|
|
|
Aug 01, 2019
|
Catalyst Pharmaceuticals Announces Its Support of Spinal Muscular Atrophy Awareness Month
CORAL GABLES, Fla. , Aug. 01, 2019 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, today
|
|
|
Jul 31, 2019
|
Catalyst Pharmaceuticals to Hold Second Quarter 2019 Financial Results Conference Call and Webcast on Thursday, August 8th, 2019
CORAL GABLES, Fla. , July 31, 2019 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, today
|
|
|
Jun 12, 2019
|
Catalyst Pharmaceuticals Files Federal Lawsuit Against U.S. Food and Drug Administration
Complaint Cites Multiple Violations of Food, Drug, and Cosmetic Act CORAL GABLES, Fla. , June 12, 2019 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq:CPRX), today announced it has filed a suit against the U.S. Food and Drug Administration ( FDA ) and several related parties
|
|
|
Jun 04, 2019
|
Catalyst Pharmaceuticals to Present at the Jefferies 2019 Global Healthcare Conference
CORAL GABLES, Fla. , June 04, 2019 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq:CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, today
|
|
|
May 30, 2019
|
Catalyst Pharmaceuticals Announces Expansion of Firdapse License to Include Japan
CORAL GABLES, Fla. , May 30, 2019 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq:CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, today
|
|
|
May 13, 2019
|
Catalyst Pharmaceuticals Announces First Quarter 2019 Financial Results and Provides Corporate Update
-Firdapse® Launch Off to Strong Start with First Quarter Net Revenues of $12.4 Million -81 Patients Without Previous Access to any Form of Amifampridine Have Been Prescribed Firdapse -Company to Host Quarterly Conference Call at 8:30 am ET Today CORAL GABLES, Fla.
|
|
|
May 06, 2019
|
Catalyst Pharmaceuticals to Hold First Quarter Financial Results Conference Call and Webcast on Monday, May 13th, 2019
CORAL GABLES, Fla. , May 06, 2019 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, today
|
|
|
Mar 18, 2019
|
Catalyst Pharmaceuticals Announces Fourth Quarter and Year-End 2018 Financial Results and Provides Corporate Update
CORAL GABLES, Fla. , March 18, 2019 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, today
|
|
|
Mar 11, 2019
|
Catalyst Pharmaceuticals to Hold Fourth Quarter Financial Results and Corporate Update Conference Call and Webcast on Tuesday, March 19th, 2019
CORAL GABLES, Fla. , March 11, 2019 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, today
|
|
